Published on 13 Oct 2023 on Zacks via Yahoo Finance
Shares of clinical-stage biopharmaceutical company Scholar Rock Holding Corporation SRRK gained 17.7% after the company announced plans to expand into the cardiometabolic disorders space and pricing of its public offering.
The company will leverage its experience in myostatin inhibition to advance SRK-439, a novel investigational myostatin inhibitor for treating cardiometabolic disorders, with an initial focus on obesity. An investigational new drug application (IND) submission is targeted in 2025.
Preclinical data support advancing SRK-439 for the treatment of obesity. Studies in diet-induced obese mice showed that SRK-439, in combination with GLP-1 receptor agonist (GLP-1 RA), achieved a dose-dependent reversal of lean mass loss during GLP-1 RA-mediated weight loss and an increase in fat mass loss mediated by GLP-1 RA treatment.